Roche sets analysts purring with strong Q3 results

Roche has beaten market expectations in third quarter results, with new drugs gaining traction and its older medicines faring better than expected against cheaper biosimilar rivals.

New price gets Clovis’ PARP inhibitor on the CDF

NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour ...

LA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that allows scientists to see inside tumours, and monitor whe

GSK joins with US biotech to toughen up cell therapies for s...

GlaxoSmithKline has announced a five-year collaboration with San Francisco biotech Lyell Immunopharma, to strengthen therapeutic T-cells before they cross the perilous area surrounding tumo

Owkin's machine learning tech to inform mesothelioma trials

A mesothelioma prognostic model from medical machine learning firm Owkin has been showcased in the journal Nature, and is being used to help further drug research into the often fatal disea

Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphoma